series-c
Stage
1
Investors
About
TORL BioTherapeutics develops antibody-based therapies, specifically antibody-drug conjugates, targeting molecular markers in solid tumors and blood cancers to treat cancer patients worldwide.
Explore TORL BioTherapeutics LLC's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.